MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enVVeno Medical Corporation - Common Stock (NQ:NVNO)

0.3500 +0.0292 (+9.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about enVVeno Medical Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
Via ACCESS Newswire
News headline image
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
Via ACCESS Newswire
News headline image
enVVeno Medical Updates Regulatory Status of VenoValve(R)
Via ACCESS Newswire
News headline image
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Via ACCESS Newswire
News headline image
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Via ACCESSWIRE
News headline image
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Via ACCESSWIRE
News headline image
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
Via ACCESS Newswire
News headline image
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Via ACCESS Newswire
News headline image
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Via ACCESS Newswire
News headline image
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
Via ACCESSWIRE
News headline image
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Via ACCESSWIRE
News headline image
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
Via ACCESSWIRE
News headline image
enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
Via ACCESS Newswire
News headline image
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
News headline image
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Via ACCESS Newswire
News headline image
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
Via ACCESS Newswire
News headline image
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
Via ACCESS Newswire
News headline image
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
Via ACCESS Newswire
News headline image
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
Via ACCESS Newswire
News headline image
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
Via ACCESS Newswire
News headline image
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
Via ACCESS Newswire
News headline image
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
Via ACCESS Newswire
News headline image
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Via ACCESSWIRE
BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story